Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3ATP2A2FXYD2
The experimentally established mechanism targets of Istaroxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 10/20 | 0.89 |
| ▸ | ATP1B1 known ✓ | P05026 | 10/20 | 0.89 |
| ▸ | ATP1A3 known ✓ | P13637 | 10/20 | 0.89 |
| ▸ | ATP1B2 known ✓ | P14415 | 10/20 | 0.89 |
| ▸ | ATP1A2 known ✓ | P50993 | 10/20 | 0.89 |
| ▸ | ATP1B3 known ✓ | P54709 | 10/20 | 0.89 |
| ▸ | FXYD2 known ✓ | P54710 | 10/20 | 0.89 |
| ▸ | ATP1A4 known ✓ | Q13733 | 10/20 | 0.89 |
| ▸ | ATP12A | P54707 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Istaroxime SCHEMBL7285898 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL8452195 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL1427268 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL7298591 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL8450412 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL1427271 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL23760714 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL5053480 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL7285904 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL22116205 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102542-A1 | ATPASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NON-NEUROLOGICAL DISORDERS | HAPLO THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | WO | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-12343350-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | claimed |
| WO-2025128432-A1 | ISTAROXIME AND METABOLITE DERIVATIVES THEREOF FOR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA | WINDTREE THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4511040-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGENIC SHOCK AND CARDIOGENIC SHOCK | Windtree Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240390323-A1 | NOVEL METHODS OF TREATING HEARING LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-11-28 | — | — | US | claimed |
| US-20240293426-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2024-09-05 | — | — | US | claimed |
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2024-07-04 | — | — | US | claimed |
| WO-2023205183-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGENIC SHOCK AND CARDIOGENIC SHOCK | WINDTREE THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| US-20230293548-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | claimed |
| US-20230181610-A1 | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2023-06-15 | — | — | US | claimed |
| US-11583540-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | claimed |
| WO-2022159678-A9 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2022159678-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220054502-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | claimed |
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-109810022-B | High-content liquid sodium benzohydroxamate and preparation and application thereof | 湖南中科矿冶技术有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583540-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | ATP2A2, ATP2A1, ATP2A3 | ATP1A1 773/4885ATP1B1 642/4885ATP1A3 255/4885 |
| US-12343350-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | ATP2A2, ATP2A1, ATP2A3 | ATP1A1 773/4885ATP1B1 642/4885ATP1A3 255/4885 |
| US-20240293426-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | TNNI3, TNNT2, TNNC1 | ATP1A1 3174/4885ATP1B1 3732/4885ATP1A3 1956/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | ATP1A1 671/4885ATP1B1 963/4885ATP1A3 826/4885 |
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | SLC5A1, CFTR, SLC5A2 | ATP1A1 4/4885ATP1B1 20/4885ATP1A3 21/4885 |
| US-20220054502-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | ATP2A2, ATP2A1, ATP2A3 | ATP1A1 773/4885ATP1B1 642/4885ATP1A3 255/4885 |
| US-20240390323-A1 | NOVEL METHODS OF TREATING HEARING LOSS | ATP2A1, ATP2A2, ATP2A3 | ATP1A1 96/4885ATP1B1 28/4885ATP1A3 31/4885 |
| US-20230181610-A1 | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations | SLC5A1, CFTR, SLC5A2 | ATP1A1 4/4885ATP1B1 9/4885ATP1A3 27/4885 |
| US-20230293548-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | ATP2A2, ATP2A1, ATP2A3 | ATP1A1 773/4885ATP1B1 642/4885ATP1A3 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.